Fulgent Genetics (FLGT) Free Cash Flow (2015 - 2026)

Fulgent Genetics has reported Free Cash Flow for 12 years, with the latest figure at -$27.6 million in Q2 2026.

• Quarterly Free Cash Flow rose 25.36% year-over-year to -$27.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$103.8 million (down 73.12% YoY) and the FY2025 annual result came in at -$124.2 million, down 545.09% from the prior year.
• Free Cash Flow declined to -$27.6 million in Q2 2026 per FLGT's latest filing, from $1.9 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $183.1 million in Q1 2022 and troughed at -$83.1 million in Q4 2025.
• A 5-year average of $3.9 million and a median of $2.6 million in 2024 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 132.29% in 2024, down 759.13% in 2024.
• Over 5 years, Free Cash Flow stood at $28.5 million in 2022, then slumped by 58.48% to $11.8 million in 2023, then soared by 79.59% to $21.2 million in 2024, then slumped by 491.35% to -$83.1 million in 2025, then surged by 66.78% to -$27.6 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$27.6 million, $1.9 million, and -$83.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.